• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    5/29/24 8:06:44 AM ET
    $BHVN
    $GENE
    $HLTH
    $IKNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHVN alert in real time by email

    Gainers

    • Reshape Lifesciences (NASDAQ:RSLS) shares increased by 82.9% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million.
    • Scorpius Holdings (AMEX:SCPX) shares moved upwards by 39.58% to $0.16. The market value of their outstanding shares is at $10.2 million. The company's, Q1 earnings came out yesterday.
    • Genetic Technologies (NASDAQ:GENE) stock rose 34.88% to $2.9. The company's market cap stands at $9.3 million.
    • Surmodics (NASDAQ:SRDX) stock increased by 17.92% to $41.39. The market value of their outstanding shares is at $590.2 million.
    • Ikena Oncology (NASDAQ:IKNA) stock increased by 17.33% to $1.56. The market value of their outstanding shares is at $75.3 million.
    • Kineta (NASDAQ:KA) stock increased by 17.27% to $0.55. The market value of their outstanding shares is at $6.7 million.

    Losers

    • Cue Health (NASDAQ:HLTH) shares decreased by 40.6% to $0.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.5 million.
    • Sharps Technology (NASDAQ:STSS) stock declined by 36.44% to $0.33. The market value of their outstanding shares is at $5.1 million.
    • Biohaven (NYSE:BHVN) shares decreased by 26.2% to $28.0. The market value of their outstanding shares is at $2.4 billion.
    • Exicure (NASDAQ:XCUR) stock decreased by 21.99% to $0.28. The market value of their outstanding shares is at $2.4 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares decreased by 17.08% to $0.34. The company's market cap stands at $5.9 million.
    • OneMedNet (NASDAQ:ONMD) stock declined by 12.94% to $1.75. The company's market cap stands at $41.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BHVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHVN
    $GENE
    $HLTH
    $IKNA

    CompanyDatePrice TargetRatingAnalyst
    Biohaven Ltd.
    $BHVN
    2/6/2026$23.00Buy
    Goldman
    Biohaven Ltd.
    $BHVN
    1/21/2026$22.00Sector Perform → Outperform
    RBC Capital Mkts
    Biohaven Ltd.
    $BHVN
    12/3/2025$11.00Buy → Neutral
    H.C. Wainwright
    Biohaven Ltd.
    $BHVN
    11/26/2025$11.00Buy → Neutral
    UBS
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    Biohaven Ltd.
    $BHVN
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    Biohaven Ltd.
    $BHVN
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    Biohaven Ltd.
    $BHVN
    9/17/2025$28.00Buy
    Citigroup
    More analyst ratings

    $BHVN
    $GENE
    $HLTH
    $IKNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

    Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity:Inflammation and Immunology:Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of Ig

    3/2/26 4:05:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    SEC Filings

    View All

    Amendment: Scorpius Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation

    8-K/A - Scorpius Holdings, Inc. (0001476963) (Filer)

    3/10/26 4:15:26 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Biohaven Ltd. (0001935979) (Filer)

    3/2/26 4:32:34 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Biohaven Ltd.

    S-8 - Biohaven Ltd. (0001935979) (Filer)

    3/2/26 4:30:08 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Biohaven with a new price target

    Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00

    2/6/26 8:10:57 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Biohaven from Sector Perform to Outperform and set a new price target of $22.00

    1/21/26 8:29:40 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Biohaven from Buy to Neutral and set a new price target of $11.00

    12/3/25 7:48:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Buten Matthew

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:09:03 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Clinical Operations Gentile Kimberly

    4 - Biohaven Ltd. (0001935979) (Issuer)

    3/3/26 6:08:17 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)

    4/A - Biohaven Ltd. (0001935979) (Issuer)

    3/9/26 6:12:05 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

    IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medical Device Directive (MDD) in May 2021, sets significantly more stringent requirements for clinical evaluation, post-market surveillance, and device traceability. Its goal is to improve patient sa

    6/3/25 8:31:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Exicure, Inc. Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen

    11/7/25 4:00:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    $GENE
    $HLTH
    $IKNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care